Ciprofloxacin-Based Triple Therapy Dosing for 44 kg Patient
For a 44 kg patient requiring ciprofloxacin-based triple therapy for H. pylori, prescribe ciprofloxacin 500 mg PO every 12 hours for 14 days, combined with a PPI twice daily and amoxicillin 1000 mg twice daily.
Rationale and Evidence
The dosing recommendation is based on FDA-approved adult ciprofloxacin dosing guidelines and H. pylori treatment consensus recommendations. While ciprofloxacin is not a first-line agent for H. pylori eradication, when used as rescue therapy (levofloxacin triple therapy being the fluoroquinolone regimen discussed in guidelines), the standard adult dose applies 1.
Key Dosing Considerations:
- Standard adult dose: The FDA label specifies 500 mg every 12 hours for most systemic infections in adults 1
- Weight consideration: At 44 kg, this patient falls within the adult dosing range (FDA adult dosing does not require weight-based adjustments for patients ≥40 kg in typical scenarios)
- Duration: All three major H. pylori guidelines (Toronto, Maastricht V/Florence, and ACG) recommend 14 days for fluoroquinolone-based triple therapy to maximize eradication rates 2
H. pylori Triple Therapy Specifics:
The complete regimen should include 2:
- PPI: Standard dose twice daily (e.g., omeprazole 20 mg, lansoprazole 30 mg, or equivalent)
- Amoxicillin: 1000 mg twice daily
- Ciprofloxacin: 500 mg twice daily
- Duration: 14 days
Important Caveats:
Ciprofloxacin is NOT a first-line option for H. pylori treatment. Levofloxacin triple therapy is the preferred fluoroquinolone regimen when fluoroquinolones are indicated 2. Ciprofloxacin-based therapy should only be considered when:
- Levofloxacin is unavailable
- Patient has failed multiple prior regimens
- Local antibiotic susceptibility data support its use
Critical administration timing: Ciprofloxacin must be taken at least 2 hours before or 6 hours after any products containing polyvalent cations (calcium, magnesium, aluminum, iron, zinc), including antacids and multivitamins 1. This is particularly important with PPI therapy if using combination products.
Renal function: If creatinine clearance is <50 mL/min, dose adjustment may be needed (250-500 mg every 12 hours for CrCl 30-50 mL/min) 1.
Resistance concerns: Fluoroquinolone resistance in H. pylori is increasing globally. This regimen should ideally be guided by susceptibility testing when available 2, 3.